Foslevodopa/foscarbidopa (Produodopa®). HTA ID: 23007

Assessment Status Rapid Review Complete
HTA ID 23007
Drug Foslevodopa/foscarbidopa
Brand Produodopa®
Indication Foslevodopa/foscarbidopa (Produodopa®) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
Assessment Process
Rapid review commissioned 13/02/2023
Rapid review completed 27/03/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Produodopa® not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.